B. Riley Securities Maintains Buy on Elicio Therapeutics, Lowers Price Target to $8
B. Riley Securities analyst Mayank Mamtani maintains Elicio Therapeutics (NASDAQ:ELTX) with a Buy and lowers the price target from $27 to $8.
Stocks · News reference
Elicio Therapeutics Announces Opening Of 20-Patient Investigator-Initiated Phase 1 Trial Of ELI-002 7P With Chemotherapy, Anti-PD1 In Neoadjuvant Pancreatic Cancer At Memorial Sloan Kettering
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — Elicio Therapeutics, Inc. (ELTX)
Filed: 2026-09-14 AccNo: 0001601485-26-000058 Size: 143 KB Item 5.08: Shareholder Nominations Pursuant to Exchange Act Rule 14a-11 Item 8.01: Other Events
Elicio Therapeutics to Participate at the H.C. Wainwright 28th Annual Global Investment Conference
Elicio Therapeutics announced that its CEO Robert Connelly and Chief Scientific Officer Pete DeMuth will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026. The clinical-stage biotech company is developing next-generation immunotherapies for KRAS-driven cancers, with its lead program ELI-002 7P targeting the most common KRAS mutations found in approximately 25% of solid tumors.
HC Wainwright & Co. Reiterates Buy on Elicio Therapeutics, Maintains $23 Price Target
HC Wainwright & Co. analyst Robert Burns reiterates Elicio Therapeutics (NASDAQ:ELTX) with a Buy and maintains $23 price target.